Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for depression prevention in aSAH survivors
NCT03826875Phase 2Completed
- Sponsor
- University of Washington
- Start
- Mar 2019
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fluoxetine in major depressive disorder (MDD) (2 arms), sponsored by University of Washington. Primary endpoint: Depression at 1 year. Started Mar 2019; status: completed.
02
Drugs
fluoxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03826875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826875.